HONG KONG, Sept. 2, 2024 /PRNewswire/ -- American singer-songwriter John Legend is set to return to Hong Kong after a six-year hiatus. Presented by Willow, co-presented by GREELIV and ADEM, and powered by Yiu Wing Live Company, John Legend will hold the concert AXA Presents: "An Evening With John Legend: A Night of Songs And Stories in Hong Kong" on 4th October, 2024 at AXA x WONDERLAND, spending an unforgettable Happy Friday with fans It promises to be a soulful and emotional experience up close with the legendary artist.
The 12-time Grammy Award winner is only the 13th artist to achieve the prestigious EGOT (Emmy, Grammy, Oscar, and Tony) and the first Black male, and second youngest recipient of the EGOT, showing his extraordinary talent across multiple disciplines.
John Legend began his musical career working behind the scenes for other artists, he worked as a session musician in playing piano and backing vocalist initially for the likes of Jay Z and Alicia Keys and Kanye West. In 2004, after signing with Kanye West's record company GOOD Music, John Legend shot to fame by releasing his debut album, Get Lifted, which received double platinum certification and spawned his first hit song, "Ordinary People", thereby massive fan base around the world. Over nearly 30-year career, John Legend has distributed numerous classic songs, including "All of Me", "Love Me Now", ' Glory', and "You & I (Nobody in the World)". It's likely that one of his songs is already part of your playlist.
As early as 2007, John Legend first connected with Hong Kong when he performed his debut concert here, drawing a large crowd of fans even as a rising star. 11years later, now a music legend, he returned to Hong Kong for a second time to hold "Darkness and Light Tour", captivating audiences once again with his stage presence and continuous pursuit of musical innovation. Those who have experienced John Legend live must being mesmerized by his expressive voice and flowing piano performances. This October, John Legend is going to Hong Kong for the third time, and Fans are on the tiptoe of expectation.
"An Evening With John Legend: A Night of Songs And Stories in Hong Kong" will take place on 4th October, 2024 at 8PM, offering VIP seats, standard seats, and standing tickets, priced at HKD 1,880, HKD 1,380, and HKD 780 respectively. Hang Seng Mastercard holderscan enjoy priority booking from 11AM on Monday, 9thSeptember, 2024 to 11:59PM on Tuesday, 10thSeptember, 2024. Tickets will go on public sale on KLOOK at 11AM on Wednesday, 11th September, 2024. Do not miss out the "LEGENDARY" show!
AXA x WONDERLAND is located at the northwestern part of the West Kowloon Cultural District, covering an area of approximately 150,000 square feet. The venue includes a large stage, dining facilities, mobile restrooms, and 200 outdoor parking spaces, with a capacity for 10,000 seated or 15,000 standing guests. The venue has hosted over 50 large-scale concerts, entertainment, cultural, and family recreation activities, promoting the development of arts, entertainment, and sports. It is the best choice for outdoor performances and events.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
12-time Grammy winner John Legend will bring his concert ' An Evening With John Legend' to Hong Kong this fall!
SHENZHEN, China, Sept. 15, 2024 /PRNewswire/ -- ImmVira announced the latest clinical results for its lead oncolytic virus product, MVR-T3011, via intravesical administration in patients with high-risk BCG-failure non-muscle invasive bladder cancer (NMIBC). The results were published through poster presentation at the 2024 European Society for Medical Oncology (ESMO 2024).
This Phase I, open-label, dose-escalation and expansion study was conducted in China to assess the safety and efficacy of MVR-T3011 administered intravesically in patients with high-risk BCG-failure NMIBC. The study enrolled a broader patient population, including those with high-grade Ta, T1, or CIS +/- Ta/T1 bladder cancer, regardless of the presence of CIS. This inclusive approach aims to target a wider range of patients, potentially accelerating future trial enrollment and expanding market opportunities. The treatment was delivered via intravesical instillation at three dose levels, with weekly induction course lasting 12 weeks, followed by bi-weekly maintenance course for up to one year.
According to poster presented (cut-off as of June 27, 2024), among 14 evaluable patients, the overall 3-month complete response (CR) rate across all dose levels was 71.4% (10/14). At the 2×109 PFU dose level (expected RP2D), the CR rate reached an impressive 87.5% (7/8). The study showed a favorable safety profile, with no dose-limiting toxicities (DLTs) reported and no maximum tolerated dose (MTD) reached. Additionally, MVR-T3011 treatment simplifies clinical procedure by eliminating the need for bladder prewash by nature, further reducing patient discomfort. The instillation process is both quick and efficient.
By September 15, 2024, the most recent data shows that 20 subjects have received MVR-T3011 treatment. At the RP2D dose level, the 3-month CR rate remained strong at 81.8% (9/11). Of the 9 patients who have reached the 6-month assessment, 8 have maintained CR, while 4 patients have reached the 9-month assessment and all remained in CR. We are continuing to gather additional data to support further analysis.
"There is a significant unmet need for innovative treatments for bladder cancer," said Dr. Grace Zhou, Chairwoman and CEO of ImmVira. "We are highly encouraged by the preliminary safety and efficacy data from this Phase I study, especially the 3-month CR rate over 80%, along with durable responses at 6- and 9-month time points. With this early success, we are committed to accelerating clinical development of intravesical MVR-T3011 treatments for BCG-failure NMIBC patients and exploring its potential across other bladder cancer indications. Our goal is to provide a novel, effective, and well-tolerated treatment solution for patients."
About MVR-T3011
MVR-T3011, ImmVira's proprietary 3-in-1 oHSV, is a novel genetic engineered oHSV with advanced backbone design aiming to achieve the most favorable profile of attenuated HSV-1 with replication potency in tumor cells and highly restricted replication in normal cells, supporting intratumoral, intravenous and intravesical administrations. Additionally, MVR-T3011 incorporated two latest and well-validated exogenous genes, PD-1 antibody and IL-12, to further enhance immune responses in the tumor microenvironment.
About ImmVira
ImmVira is a biotechnology company focused on developing and synthesizing biological vector delivery platform. The company has constructed a fully integrated OVPENS® (Open Vector+ Potent, Enabling, Novel & Safe) platform with solid science, technology and CMC know-how, and three derivative subplatforms including Oncolytic Virus, Cancer Vaccine and Biosynthetic Exosome, to support ongoing R&D, clinical studies and commercialization of best-in-class mono and combo therapies driven by clinical benefits in oncology and non-oncology fields.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients
ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients
ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients
